H. Shimodaira

发表

Screening the p53 status of human cell lines using a yeast functional assay

R. Kanamaru, C. Ishioka, M. Akiyama, 1997, Molecular carcinogenesis.

Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2016 for the Clinical Practice of Hereditary Colorectal Cancer (Translated Version)

N. Tomita, Masahiro Yoshida, H. Ueno, 2018, Journal of the Anus Rectum and Colon.

High throughput RNAi screening identifies ID1 as a synthetic sick/lethal gene interacting with the common TP53 mutation R175H

S. Kato, C. Ishioka, Y. Kakudo, 2013, Oncology reports.

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial

C. Ishioka, H. Shimodaira, S. Morita, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.

N. Sugimoto, I. Hyodo, H. Shimodaira, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety Verification Trials of mFOLFIRI and Sequential IRIS + Bevacizumab as First- or Second-Line Therapies for Metastatic Colorectal Cancer in Japanese Patients

S. Kato, C. Ishioka, Takao Suzuki, 2012, Oncology.

Multidisciplinary approach to a case of Lynch syndrome with colorectal, ovarian, and metastatic liver carcinomas

C. Ishioka, Y. Kakudo, H. Shimodaira, 2012, International Cancer Conference Journal.

Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers

Kazunori Otsuka, H. Shibata, C. Ishioka, 2021, Cancer Chemotherapy and Pharmacology.

Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer

S. Kato, C. Ishioka, Takao Suzuki, 2013, International Journal of Clinical Oncology.

Guidelines for treatment of renal injury during cancer chemotherapy 2016

C. Ishioka, H. Nishiyama, M. Nangaku, 2017, Clinical and Experimental Nephrology.

Functional analysis of human MLH1 mutations in Saccharomyces cerevisiae

S. Friend, P. Radice, H. Shibata, 1998, Nature Genetics.

Patient perceptions of curability and physician-reported disclosures of incurability in Japanese patients with unresectable/recurrent cancer: a cross-sectional survey

C. Ishioka, H. Shimodaira, Kazuki Sato, 2018, Japanese journal of clinical oncology.

Functional analysis of human MLH1 variants using yeast and in vitro mismatch repair assays.

C. Ishioka, R. Iggo, R. Kolodner, 2007, Cancer research.

Acute exacerbation of paraneoplastic neurological syndrome after massive tumor lysis of neuroendocrine carcinoma by chemoradiotherapy

S. Kato, C. Ishioka, H. Shimodaira, 2013, International Cancer Conference Journal.

Upper Arm Central Venous Port Implantation: A 6-Year Single Institutional Retrospective Analysis and Pictorial Essay of Procedures for Insertion

S. Kato, C. Ishioka, Y. Kakudo, 2014, PloS one.

A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.

E. Oki, H. Shimodaira, M. Azuma, 2018, European journal of cancer.

Efficacy and safety of denosumab versus zoledronic acid in delaying skeletal-related events in patients with gastrointestinal cancer, pancreas-biliary system cancer, and other rare cancers

C. Ishioka, H. Shimodaira, Masahiro Takahashi, 2017 .

474OTreatment outcome according to tumor RAS mutation status in TRICOLORE trial: A randomized phase 3 trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer

C. Ishioka, Masato Nakamura, Hiroyuki Takahashi, 2017 .

Apoptotic function of human PMS2 compromised by the nonsynonymous single-nucleotide polymorphic variant R20Q

R. Kolodner, W. Edelmann, H. Shimodaira, 2008, Proceedings of the National Academy of Sciences.

Functional Complementation Assay for 47 MUTYH Variants in a MutY-Disrupted Escherichia Coli Strain

C. Ishioka, H. Shimodaira, Masanobu Takahashi, 2015, Human mutation.

Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3‐kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3‐kinase dual inhibitors

C. Ishioka, O. Takahashi, A. Oda, 2012, Cancer science.

Randomized phase III study of irinotecan (CPT-11) versus weekly paclitaxel (wPTX) for advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of fluoropyrimidine plus platinum (FP): WJOG4007 trial.

N. Sugimoto, I. Hyodo, H. Shimodaira, 2012 .

Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors

C. Ishioka, A. Oda, H. Shimodaira, 2015, Cancer science.

OLA1 gene sequencing in patients with BRCA1/2 mutation-negative suspected hereditary breast and ovarian cancer

C. Ishioka, H. Shimodaira, Takahiro Mori, 2017, Breast Cancer.

Detection of heterozygous truncating mutations in the BRCA1 and APC genes by using a rapid screening assay in yeast.

K. Isselbacher, M. FitzGerald, D. Haber, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin

R. Kolodner, H. Shimodaira, Jean Y. J. Wang, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal Cancer

N. Tomita, K. Kumamoto, T. Takayama, 2021, International Journal of Clinical Oncology.

A new combination chemotherapy with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for advanced esophageal cancers.

S. Kato, H. Shibata, R. Kanamaru, 1999, Internal medicine.

Analysis of the human APC mutation spectrum in a saccharomyces cerevisiae strain with a mismatch repair defect

Kazunori Otsuka, H. Shibata, R. Kanamaru, 2003, International journal of cancer.

Efficacy and Safety of Carboplatin and Etoposide Combination Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma: A Retrospective Case Series

C. Ishioka, H. Shimodaira, Masanobu Takahashi, 2015, Chemotherapy.

Phase II Trial of Cetuximab plus Irinotecan for Oxaliplatin- and Irinotecan-Based Chemotherapy-Refractory Patients with Advanced and/or Metastatic Colorectal Cancer: Evaluation of Efficacy and Safety Based on KRAS Mutation Status (T-CORE0801)

S. Kato, C. Ishioka, Y. Kakudo, 2014, Oncology.

Phase II Trial of Cetuximab plus Irinotecan for Oxaliplatin-and Irinotecan-Based Chemotherapy-Refractory Patients with Advanced and / or Metastatic Colorectal Cancer : Evaluation of Efficacy and Safety Based on KRAS Mutation Status ( T-CORE 0801 )

S. Kato, C. Ishioka, Y. Kakudo, 2014 .

Oligomerization is not essential for growth suppression by p53 in p53-deficient osteosarcoma Saos-2 cells.

R. Kanamaru, C. Ishioka, C. Englert, 1997, Biochemical and biophysical research communications.

KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin-or irinotecan-based treatment.

S. Kato, C. Ishioka, M. Gamo, 2014, Molecular and clinical oncology.

Successful sequential treatment of a patient with advanced gastrointestinal stromal tumor using four different molecularly targeted drugs

C. Ishioka, H. Shimodaira, Masanobu Takahashi, 2016, International Cancer Conference Journal.

Aberrant splicing caused by a MLH1 splice donor site mutation found in a young Japanese patient with Lynch syndrome

Yusuke Nakamura, Y. Furukawa, C. Ishioka, 2012, Familial Cancer.

microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer

C. Ishioka, H. Shimodaira, S. Ohnuma, 2017, BMC Cancer.

Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.

Kazuhiro Yoshida, H. Shimodaira, S. Morita, 2017, The lancet. Gastroenterology & hepatology.

Functional analysis of human MLH1 mutations in Saccharomyces cerevisiae

H. Shimodaira, 1999, Nature Genetics.

Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation

S. Kato, H. Shibata, C. Ishioka, 2006, International Journal of Clinical Oncology.

Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis

C. Ishioka, H. Shimodaira, Takahiro Mori, 2017, PloS one.

CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer

C. Ishioka, H. Shimodaira, M. Inoue, 2016, International Journal of Clinical Oncology.

DNA methylation status as a biomarker of anti‐epidermal growth factor receptor treatment for metastatic colorectal cancer

H. Aburatani, C. Ishioka, K. Tatsuno, 2015, Cancer science.

Detection of APC mutations by a yeast‐based protein truncation test (YPTT)

R. Kanamaru, C. Ishioka, Takao Suzuki, 1998, Genes, chromosomes & cancer.

The G8 screening tool enhances prognostic value to ECOG performance status in elderly cancer patients: A retrospective, single institutional study

Chikashi Ishioka, Yuki Kasahara, C. Ishioka, 2017, PloS one.

Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer

S. Kato, H. Shibata, C. Ishioka, 2009, British Journal of Cancer.

Intermittent Withdrawal of Oxaliplatin for Alleviating Neurotoxicity during Oxaliplatin-Based Chemotherapy for Japanese Patients with Inoperable or Metastatic Colorectal Cancer: A Phase 2 Multicenter Study.

S. Kato, C. Ishioka, H. Shimodaira, 2018, The Tohoku journal of experimental medicine.

First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study

E. Baba, N. Sugimoto, I. Hyodo, 2018, Gastric Cancer.

Gene-expression profiles correlate with the efficacy of anti-EGFR therapy and chemotherapy for colorectal cancer

S. Kato, C. Ishioka, H. Shimodaira, 2015, International Journal of Clinical Oncology.

Cisplatin Plus Capecitabine After Adjuvant S-1 in Metastatic Gastric Cancer: A Phase II T-CORE1102 Trial

C. Ishioka, H. Shimodaira, Takuhiro Yamaguchi, 2022, AntiCancer Research.

Phase II trial of cetuximab plus irinotecan for FOLFOX and FOLFIRI-refractory patients with EGFR-positive advanced and/or metastatic colorectal cancer: Evaluation of the efficacy and safety based on KRAS mutation status (T- CORE0801).

S. Kato, C. Ishioka, H. Shimodaira, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022

H. Shimodaira, Y. Ando, A. Yonezawa, 2023, International Journal of Clinical Oncology.

Attainment of a Long-term Favorable Outcome by Sunitinib Treatment for Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Associated with von Hippel-Lindau Disease.

C. Ishioka, T. Shuin, H. Shimodaira, 2016, Internal medicine.

Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2016 for the Clinical Practice of Hereditary Colorectal Cancer (Translated Version)

N. Tomita, Masahiro Yoshida, H. Ueno, 2018, Journal of the anus, rectum and colon.

Attainment of a Long-term Favorable Outcome by Sunitinib Treatment for Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Associated with von Hippel-Lindau Disease.

C. Ishioka, T. Shuin, H. Shimodaira, 2016, Internal medicine.

[Antibody-dependent cellular cytotoxicity in the immunotherapeutic mechanisms of anti-EGFR monoclonal antibody].

C. Ishioka, H. Shimodaira, K. Komine, 2010, Gan to kagaku ryoho. Cancer & chemotherapy.